We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

7832:TSEBandai Namco Holdings Inc. Analysis

Data as of 2026-05-21 - not real-time

NT$12.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Intelligene’s stock sits in a tight range around TWD 12, flirting with its 20‑day SMA while lagging well behind the 50‑day SMA, signaling a lack of upward momentum.
Technical gauges paint a mixed picture: the 14‑day RSI is deep in oversold territory, the MACD line and histogram are both negative and the MACD signal is flagged as bearish, and volatility over the past month is above 20 %, all of which suggest short‑term price pressure but also a potential bounce from the oversold condition.
Fundamentally, the company is on shaky ground – revenue has contracted, operating and profit margins are deeply negative, cash‑flow is out of the black, debt‑to‑equity is near five‑to‑one and the price‑to‑book multiple sits well above seven, indicating the market price is considerably higher than intrinsic book value.
Coupled with an “Extreme Greed” reading on the fear‑and‑greed index, a very low beta and a high max‑drawdown, the stock carries pronounced risk across sector, regulatory and liquidity dimensions, making it a speculative play rather than a value proposition.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • oversold RSI indicating potential short‑term bounce
  • bearish MACD signal reinforcing downward pressure
  • price near identified support level around 11.9 TWD

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • negative earnings and operating margin
  • high debt‑to‑equity ratio stressing balance sheet
  • persistent negative cash‑flow and free cash‑flow

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • ongoing operating losses with no earnings outlook
  • price-to‑book and price‑to‑sales multiples far above industry norms
  • significant regulatory uncertainty in the RNA‑gene‑therapy space

Key Metrics & Analysis

Financial Health

Revenue Growth-55.00%
ROE-18.77%
ROA-11.11%
Debt/Equity4.91
P/B Ratio7.6
Op. Cash FlowNT$-122465000
Free Cash FlowNT$-127909504
Industry P/E27.1

Technical Analysis

TrendNeutral
RSI27.0
SupportNT$11.90
ResistanceNT$13.85
MA 20NT$12.86
MA 50NT$13.24
MA 200NT$12.66
MACDBearish
VolumeIncreasing
Fear & Greed Index90.29

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta0.13
Volatility21.53%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.